Results 141 to 150 of about 66,261 (304)

Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options

Effective Pharmacotherapy
Dipeptidyl peptidase 4 inhibitors are a new innovative class of glucose-lowering drugs. The drugs belong to the group of incretin mimetics, prolonging the action of their own incretins. Since 2007, the list of proposed dipeptidyl peptidase 4 inhibitors has expanded significantly and significant experience in their use has accumulated.
S.V. Podachina, I.V. Soloviova
openaire   +1 more source

Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists

Journal of Diabetes Investigation, EarlyView.
Future directions in incretin research: Three major directions currently shape therapeutic innovation in incretin research: multi‐receptor agonism, oral drug development, and mechanistic reappraisal of glucose‐dependent insulinotropic polypeptide (GIP) physiology.
Sodai Kubota, Yutaka Seino, Daisuke Yabe
wiley   +1 more source

Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction

Journal of Diabetes Investigation, EarlyView.
In a woman with KCNJ11‐related permanent neonatal diabetes mellitus, incretin‐based therapy enabled insulin discontinuation and maintained glycemic control for more than 5 years, with HbA1c between 6.1% and 6.5% on the lowest semaglutide dose, dose‐dependent improvement in insulin secretion, and an approximately 60% reduction in glibenclamide dose ...
Toshiaki Ohkuma, Ryoichiro Aotani, Wakako Sakamoto, Ayaka Oshiro, Tetsuro Ago   +4 more
wiley   +1 more source

Serum dipeptidyl peptidase-4 in chronic liver disease patients with osteoporosis

Egyptian Liver Journal
Background and aim Fibrosis and cirrhosis are the results of the progressive degradation and regeneration of the liver parenchyma in chronic liver disease (CLD).
Nashwa Farouk Mohamed Elmetwaly, Ola G. Behairy, Manal S. Eldefrawy, Dina Saad Abdelmotaleb, Elham Kamal Ahmed El Battawy   +4 more
doaj   +1 more source

Life‐threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry‐based cross‐sectional study

Journal of Diabetes Investigation, EarlyView.
Despite insulin therapy, 18.8 and 7.8% of the patients experienced diabetic ketosis and diabetic ketoacidosis, respectively. Furthermore, 12.7 and 28.9% of the participants experienced severe hypoglycemia and hypoglycemic unawareness, respectively. Lower C‐peptide levels were associated with the incidence of these complications.
Daisuke Chujo, Akihisa Imagawa, Junnosuke Miura, Kazuma Takahashi, Toru Kikuchi, Ichiro Horie, Daisuke Yabe, Akira Shimada   +7 more
wiley   +1 more source

Impact of COVID‐19 restrictions and their relaxation on body composition and glycemic control in individuals with glucose intolerance in Japan: A single‐center observational study

Journal of Diabetes Investigation, EarlyView.
This study examined glycemic control, body composition, and lifestyle changes in 221 outpatients with glucose intolerance (GI) in Japan across the pre‐state of emergency (SOE), SOE, and post‐SOE periods. HbA1c increased despite body weight reduction, with progressive muscle loss.
Ami Kobayashi, Yamato Keidai, Takaaki Murakami, Ryo Tsukaguchi, Miharu Fujita, Keiko Wada, Daisuke Yabe   +6 more
wiley   +1 more source

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, EarlyView.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors

Drug Design, Development and Therapy, 2015
Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Shoombuatong W, Prachayasittikul V, Anuwongcharoen N, Songtawee N, Monnor T, Prachayasittikul S, Prachayasittikul V, Nantasenamat C   +7 more
doaj  

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source